PLT Health Solutions Inc. has received a license from the Natural and Non-Prescription Health Products Directorate (NNHPD) of Health Canada to market its ingredient AlvioLife to support respiratory health in Canada.
PLT Health Solutions Inc. (Morristown, NJ) has received a license from the Natural and Non-Prescription Health Products Directorate (NNHPD) of Health Canada to market its ingredient AlvioLife to support respiratory health in Canada. The ingredient is composed of a proprietary formula containing extracts of Boswellia serrata gum resin [standardized to 30% 3-O-acetyl-11-keto-ß-boswellic acid (AKBA)] and Aegle marmelos dried fruit. AlvioLife is clinically supported to help improve overall respiratory health, maintain clear airways, protect against environmental exposure, and sooth respiratory tissues, says PLT Health.
For example, one double-blind, placebo-controlled study published in Phytotherapy Research1 found that 200 mg per day of AlvioLife for 56 days significantly improved response to environmental stimuli and breathing scores, compared to placebo. Specifically, subjects taking AlvioLife saw significant improvements in Peak Expiratory Flow (L/min), compared to placebo, on day 56, as well as Expiratory Volume 1 on day 56, compared to placebo group with saw no improvement. Subjects taking AlvioLife also saw improvements in quality of life with activity limitation and emotional function scores significantly improving on day 14, with further improvements on day 28 and 56, compared to placebo.
Canada has approved the following claims:
“Respiratory health is at the top of everyone’s minds these days. AlvioLife is an interesting ingredient both as a standalone but also as a compliment to immune support ingredients,” explained Barbara Davis, PhD, head of Clinical and Regulatory Sciences for PLT Health Solutions, in a press release. “The anti-inflammatory effects, particularly 5-lipoxygenase (5-LOX) inhibition by AKBA and quince fruit, are responsible for its effectiveness in supporting respiratory health. Accumulating and significant evidence suggests that 5‐LOX has profound influence on the onset and progression of airway inflammation.”